---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-084049"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2025-08-27T23:59:59+00:00"
generated_at: "2026-05-17T09:36:14.092405+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA approves Novavax's Nuvaxovid 2025-2026 COVID-19 vaccine for high-risk populations

## Summary
- Approved for adults 65+ and high-risk individuals 12-64; only protein-based non-mRNA COVID-19 vaccine available in U.S. for 2025-2026 season.
- Shelf life extended from 3 to 6 months for the 2025-2026 formula.
- FDA requires two postmarketing studies: a Phase 3 safety/immunogenicity study and a Phase 4 placebo-controlled trial on post-COVID vaccination syndrome.
- Sanofi to lead commercialization; Novavax receives tiered royalties on sales.
- Clinical data show JN.1 strain induces immunity against multiple JN.1 lineage variants including NB.1.8.1 and XEC.

## SEC filing metadata
- accession: 0001104659-25-084049
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2025-08-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465925084049/0001104659-25-084049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465925084049/tm2524511d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-084049
- JSON: https://secwatch.observer/filing/0001104659-25-084049.json
- Plain text: https://secwatch.observer/filing/0001104659-25-084049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.